Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
MHLW OKs First Generics for Tracleer, 6 Other APIs towards December Listing
The Ministry of Health, Labor and Welfare (MHLW) on August 15 approved first generics for seven active pharmaceutical ingredients (APIs) towards their reimbursement listing in December, including those for Actelion Pharmaceuticals’ pulmonary arterial hypertension (PAH) drug Tracleer (bosentan). Tracleer is…
To read the full story
Related Article
- Talion AG, 2 Other APIs Skip December Gx Listing
December 8, 2016
- First Generics for 5 APIs to Join NHI Price List on Dec. 9
December 8, 2016
- Kipres Generics Might Add Bronchial Asthma Indication before December Listing
October 21, 2016
- Kipres/Singulair to Face Generic Onslaught in Dec.; Competition to Hit Tracleer, Too
August 4, 2016
REGULATORY
- MHLW Set to Launch Searchable Drug Supply Database in April
February 3, 2026
- MHLW Pushes Back GCP Ordinance Revision to Summer
February 3, 2026
- Public Comments Warn Japan’s Drug Pricing System Cannot Reflect Inflation: Chuikyo
February 2, 2026
- Chuikyo Agrees to Apply Originator Optimal-Use Guidelines to Biosimilars
February 2, 2026
- MHLW Panel Sets Safety Rules for Upcoming Pomalyst Generics
February 2, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…